O-specific side-chain toxin-protein conjugates parenteral vaccines prevention shigellosis related diseases indirect evidence lipopolysaccharide-mediated virulence bacterial level serum antibodies O-specific side chain lipopolysaccharide molecule shigellosis use subunit Shiga toxin carrier protein evidence indirect serum antitoxin severity dysentery diarrhea animal models disease information inapplicable prediction vaccine-induced protective immunity clinical trials population risk successful completion safety immunogenicity phases vaccine development laboratory animals target population Clinical studies shigella vaccines difficult many causes dysentery population high rate intestinal disease 